TO EVALUATE EFFECT OF BRAHMI VATI & SARASWATARISHTA IN ANXIETY (EXCESSIVE WORRY)

EFFICACY OF BRAHMI VATI WITH SARASWATARISHTA OVER ESCITALOPRAM IN GENERALIZED ANXIETY DISORDER -A RANDOMIZED CONTROLLED CLINICAL TRIAL

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/09/027750

Enrollment

Registered

2020-09-11

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F01-F99- Mental, Behavioral and Neurodevelopmental disorders

Interventions

Intervention1: Brahmi Vati & Saraswatarishta: Brahmi Vati 500 mg TID with Saraswatarishta (without gold) 10 ml TID for 60 days Control Intervention1: Escitalopram: Escitalopram 10 mg for first 10 days

Eligibility

Inclusion criteria

Inclusion criteria: 1 Subjects fulfilling the diagnostic criteria of GAD (DSM V)

Exclusion criteria

Exclusion criteria: 1 Laxana of Unmada (co-morbid psychiatric disorders) 2 Psychotropic drugs four weeks prior to study. 3 Patients with substance abuse like alcohol etc. 4 Patients with significant depression (BDI >17). 5 The patients with any other medical (Hypertension, Diabetes Mellitus) 6 Female patients who are pregnant and lactating.

Design outcomes

Primary

Measure	Time frame
Improvement in anxiety assessment scaleTimepoint: 0th day 15th day 30th day 45th day 60th day	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDR BASAVARAJ TUBAKI

KAHERs Shri BMK Ayurveda Mahavidyalaya

ayurbasavaraj@gmail.com9448634660

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 5, 2026